Press Releases

Cross-border initiative expands Lōkahi’s university network, increases capacity for additional revenue generating strategic partnerships, and brings together U.S. and German students to identify and evaluate international therapeutic assets with potential for U.S. development and commercialization RUTHERFORD, N.J. & LA JOLLA, Calif. – Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced a new…

Developed Through ai² Accelerator™, Qare™ Is Designed to Enable Users to Compare Their Experiences Against Cohorts of People Like Them, with Additional Drug Classes Expected to Follow RUTHERFORD, N.J. & LA JOLLA, Calif. – Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced Qare™, a comparative health platform designed to evaluate treatment outcomes…

RUTHERFORD, N.J. & LA JOLLA, Calif. – Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced that it will partner with Pepperdine E2B™ (Education to Business) to engage students in its ai2 Pipeline™ initiative during the upcoming academic year. The collaboration is intended to provide students with hands-on experience evaluating real-world biopharmaceutical opportunities…

RUTHERFORD, N.J. & LA JOLLA, Calif. – Glucotrack, Inc. (NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced the pricing of a “best efforts” public offering of 169,388 shares of common stock at a price of $2.04 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase up to…

Innovate GBM becomes the first external organization to engage the ai² Division on a fee-for-service basis to identify brain tumor therapeutic assets for potential licensing and development RUTHERFORD, N.J. & LA JOLLA, Calif. & LOS ANGELES – Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced that Innovate GBM, a 501(c)(3) nonprofit…

RUTHERFORD, N.J. & LA JOLLA, Calif. – Lōkahi Therapeutics™ today issued a strategic corporate update highlighting progress in its LT-100 development program, expansion of its ai² platform, and priorities for advancing and monetizing differentiated therapeutic assets. A Clear View of Who We Are A Message From Our CEO, Erik Emerson Good morning. I’m Erik Emerson,…

RUTHERFORD, N.J. & LA JOLLA, Calif. – Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced that The University of Alabama’s Culverhouse College of Business will continue its participation in the ai² Pipeline division for the upcoming academic year. The renewed collaboration extends a hands-on program in which students evaluate real-world biopharmaceutical business…

RUTHERFORD, N.J. & LA JOLLA, Calif. – Glucotrack, Inc. (NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced definitive agreements for convertible notes with an aggregate principal amount of approximately $11.5 million, including approximately $4.5 million of new cash investment and approximately $4.5 million of existing notes being rolled over, with the aggregate principal amount reflecting…

ai² Pipeline™, ai² Talent™, and ai² Accelerator™ create potential revenue-generating opportunities while strengthening Lōkahi’s therapeutic development platform. RUTHERFORD, N.J., & LA JOLLA, Calif. – Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced the expansion of its ai² platform into three dedicated business divisions: ai² Pipeline™, ai² Talent™, and ai² Accelerator™. The…

RUTHERFORD, N.J., & LA JOLLA, Calif. – Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced a collaboration with San Diego State University’s (SDSU) Fowler College of Business, expanding the ai² Futures Lab™ and strengthening Lōkahi’s growing network of partner academic institutions. The partnership with SDSU furthers Lōkahi’s work to identify and evaluate…